TWI573806B - 生物活性胜肽 - Google Patents

生物活性胜肽 Download PDF

Info

Publication number
TWI573806B
TWI573806B TW103127214A TW103127214A TWI573806B TW I573806 B TWI573806 B TW I573806B TW 103127214 A TW103127214 A TW 103127214A TW 103127214 A TW103127214 A TW 103127214A TW I573806 B TWI573806 B TW I573806B
Authority
TW
Taiwan
Prior art keywords
peptide
prt
artificial sequence
synthetic peptide
seq
Prior art date
Application number
TW103127214A
Other languages
English (en)
Chinese (zh)
Other versions
TW201443085A (zh
Inventor
費德瑞奇 雪佛玲格
麥克 多卡爾
Original Assignee
巴克斯歐塔公司
巴克斯歐塔有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴克斯歐塔公司, 巴克斯歐塔有限公司 filed Critical 巴克斯歐塔公司
Publication of TW201443085A publication Critical patent/TW201443085A/zh
Application granted granted Critical
Publication of TWI573806B publication Critical patent/TWI573806B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW103127214A 2008-04-17 2009-04-15 生物活性胜肽 TWI573806B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10

Publications (2)

Publication Number Publication Date
TW201443085A TW201443085A (zh) 2014-11-16
TWI573806B true TWI573806B (zh) 2017-03-11

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103127214A TWI573806B (zh) 2008-04-17 2009-04-15 生物活性胜肽
TW098112448A TWI541020B (zh) 2008-04-17 2009-04-15 生物活性胜肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW098112448A TWI541020B (zh) 2008-04-17 2009-04-15 生物活性胜肽

Country Status (19)

Country Link
US (6) US8563688B2 (OSRAM)
EP (2) EP2279200B1 (OSRAM)
JP (3) JP6038452B2 (OSRAM)
KR (2) KR101606248B1 (OSRAM)
CN (2) CN105524163A (OSRAM)
AR (1) AR071478A1 (OSRAM)
AU (1) AU2009244635B2 (OSRAM)
BR (1) BRPI0911203A2 (OSRAM)
CA (1) CA2721694C (OSRAM)
DK (2) DK2279200T3 (OSRAM)
ES (2) ES2594706T3 (OSRAM)
HK (1) HK1223946A1 (OSRAM)
MX (1) MX2010011397A (OSRAM)
NZ (1) NZ588200A (OSRAM)
PL (1) PL2279200T3 (OSRAM)
PT (1) PT2279200T (OSRAM)
SG (2) SG10201608071YA (OSRAM)
TW (2) TWI573806B (OSRAM)
WO (1) WO2009137256A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
CN103262532B (zh) 2010-07-19 2018-03-09 杜比实验室特许公司 用于经采样复用的图像和视频数据的增强方法
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2014200126A1 (ko) * 2013-06-11 2014-12-18 씨제이제일제당 (주) Ｌ-이소루신을 생산하는 미생물 및 이를 이용한 ｌ-이소루신 제조방법
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 ＡｖａｎＳｔｒａｔｅ株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
JP7035033B2 (ja) 2016-09-28 2022-03-14 コーバー、インコーポレイテッド 治療用ＭＯＴＳ－ｃ関連ペプチド
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124544A1 (en) * 2001-10-17 2005-06-09 Claude Granier Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1996021024A1 (en) * 1994-12-30 1996-07-11 Asgrow Seed Company Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
EP1196432A2 (en) 1999-07-02 2002-04-17 Genentech, Inc. FVIIa ANTAGONISTS
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
EP1257289A1 (en) * 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2002256518B2 (en) * 2001-05-11 2007-07-19 Research Development Foundation Inhibitors of receptor activator of NF-kappaB and uses thereof
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
EP1968999A2 (en) * 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
KR20080090489A (ko) 2006-01-04 2008-10-08 두-쿱 테크놀로지스 리미티드 살균제 조성물 및 그 사용 방법
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124544A1 (en) * 2001-10-17 2005-06-09 Claude Granier Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI GenBank: AB102675，2004/3/30. *

Also Published As

Publication number Publication date
TW200944226A (en) 2009-11-01
HK1154255A1 (zh) 2012-04-13
EP2279200B1 (en) 2016-07-13
EP3115370A1 (en) 2017-01-11
US10822376B2 (en) 2020-11-03
CA2721694C (en) 2018-11-06
US20100022445A1 (en) 2010-01-28
PT2279200T (pt) 2016-10-12
US10287319B2 (en) 2019-05-14
CN102007140A (zh) 2011-04-06
JP2014074052A (ja) 2014-04-24
KR20130112959A (ko) 2013-10-14
KR20110005873A (ko) 2011-01-19
ES2594706T3 (es) 2016-12-22
CA2721694A1 (en) 2009-11-12
JP6038452B2 (ja) 2016-12-07
PL2279200T3 (pl) 2017-08-31
WO2009137256A1 (en) 2009-11-12
SG10201809286XA (en) 2018-11-29
JP2011518179A (ja) 2011-06-23
MX2010011397A (es) 2010-11-12
HK1223946A1 (zh) 2017-08-11
ES2739676T3 (es) 2020-02-03
CN105524163A (zh) 2016-04-27
US20120077749A1 (en) 2012-03-29
US20150038676A1 (en) 2015-02-05
EP3115370B1 (en) 2019-06-26
TW201443085A (zh) 2014-11-16
TWI541020B (zh) 2016-07-11
NZ588200A (en) 2012-11-30
JP2017019797A (ja) 2017-01-26
JP5977223B2 (ja) 2016-08-24
KR101606248B1 (ko) 2016-03-24
AU2009244635B2 (en) 2012-04-19
US9598464B2 (en) 2017-03-21
AU2009244635A1 (en) 2009-11-12
US8563688B2 (en) 2013-10-22
BRPI0911203A2 (pt) 2016-07-05
DK2279200T3 (en) 2016-08-22
US20170174724A1 (en) 2017-06-22
US8822638B2 (en) 2014-09-02
US9206234B2 (en) 2015-12-08
US20190225648A1 (en) 2019-07-25
DK3115370T3 (da) 2019-07-29
SG10201608071YA (en) 2016-11-29
AR071478A1 (es) 2010-06-23
KR101434712B1 (ko) 2014-10-01
US20160060295A1 (en) 2016-03-03
EP2279200A1 (en) 2011-02-02
CN102007140B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
TWI573806B (zh) 生物活性胜肽
AU2019202888B2 (en) Biologically active peptides
AU2012205202B2 (en) Biologically Active Peptides
HK1233275B (en) Biologically active peptides
HK1233275A (en) Biologically active peptides
HK1233275A1 (en) Biologically active peptides